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Abstract Objective: We investigated whether diﬀerences
in pharmacokinetics of midazolam, a CYP3A probe,
could be demonstrated between subjects with diﬀerent
CYP3A4 and CYP3A5 genotypes.
Methods: Plasma concentrations of midazolam, and of
total (conjugated + unconjugated) 1¢OH-midazolam,
and 4¢OH-midazolam were measured after the oral
administration of 7.5 mg or of 75 lg of midazolam in 21
healthy subjects.
Results: CYP3A5*7, CYP3A4*1E, CYP3A4*2,
CYP3A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*8,
CYP3A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17
and CYP3A4*18 alleles were not identiﬁed in the 21
subjects. CYP3A5*3, CYP3A5*6, CYP3A4*1B and
CYP3A4*1F alleles were identiﬁed in 20, 1, 4 and 2
subjects, respectively. No statistically signiﬁcant diﬀer-
ences were observed for the AUCinf values between the
diﬀerent genotypes after the 75-lg or the 7.5-mg dose.
Conclusion: Presently, CYP3A4 and CYP3A5 genotyp-
ing methods do not suﬃciently reﬂect the inter-individ-
ual variability of CYP3A activity.
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Introduction
Because of its abundance in the intestine and liver,
CYP3A, a term that in adults reﬂects the collective
activity of CYP3A4 and CYP3A5, plays a central role
in the metabolism of a wide variety of therapeutic
compounds [1]. Considering the large inter-individual
and intra-individual variability in CYP3A activity,
characterisation of CYP3A activity either by genotyping
or phenotyping methods is needed. With regard to
genotyping methods, several allelic variants have been
characterised for CYP3A4, although these variants pre-
dict only to a very limited extent the observed inter-
individual variability of CYP3A4 activity [2, 3]. Several
variants have also been described for CYP3A5, the most
common CYP3A5*3 allele causing the loss of hepatic
CYP3A5, and only people with at least one CYP3A5*1
allele express large amounts of CYP3A5 [4, 5]. Because
CYP3A5 represents up to 50% of the total hepatic
CYP3A content, it has been suggested that polymor-
phically expressed CYP3A5 may be an important genetic
contributor to inter-individual diﬀerences in CYP3A-
dependent drug clearance [4]. CYP3A5 is the prevailing
CYP3A isoform in kidney, and *1/*3 individuals had at
least an 8-fold higher mean kidney microsomal CYP3A5
content and an 18-fold higher mean CYP3A catalytic
activity than *3/*3 individuals [6]. Furthermore, the *3
allele was associated with systolic blood pressure, mean
arterial pressure, and creatinine clearance among 25
healthy African-American adults [6]. However, there is a
large overlap of activity between CYP3A4 and CYP3A5,
and a recent study with Chinese people showed that the
pharmacokinetics of midazolam (MID), a substrate of
both isozymes, is independent of CYP3A5 expression [7].
In another recent study, no signiﬁcant association was
found between homozygosity for the inactivating
CYP3A5mutations andMID or erythromycin metabolic
elimination in 57 healthy men and women of either
European-American or African-American ancestry [8].
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MID is a widely accepted probe for phenotyping
CYP3A activity [1, 9, 10]. Following oral administra-
tion, MID is oxidised to 1¢-OH midazolam (1OHMID)
and 4¢-OH midazolam (4OHMID) [1]. To validate the
use of a very low (75 lg) oral dose of MID as a
phenotyping probe for CYP3A, we measured the
kinetics of oral doses of 75 lg MID in 21 healthy
subjects free of drugs known as being CYP3 inducers
or inhibitors. In addition, the kinetics of an oral dose
of 7.5 mg MID was also measured in a subset of 13
subjects [11]. The aim of this study was to test whether
diﬀerent CYP3A4 or CYP3A5 genotypes can explain
diﬀerences in MID pharmacokinetics in this group of
21 subjects.
Subjects and methods
Study design
The protocol of the study on the validation of the very
low oral dose of MID for CYP3A phenotyping is de-
scribed in detail elsewhere [11]. In summary, the study
population consisted of 21 healthy volunteers (19 Cau-
casian, 1 North African, 1 black African, 8 male) who
were all free of drugs with the exception of a subject with
an oral contraceptive. The study was approved by the
ethics committee of the University Department of Psy-
chiatry, and all subjects gave their written informed
consent to participate in the study. Subjects had normal
hepatic and renal functions, as assessed by standard
clinical laboratory tests (ALT, ASP, AP, GGT, urea,
creatinine).
The present study was based on pharmacokinetic
data obtained in the whole group of 21 subjects
following the administration of an oral dose of 75 lg
MID. The pharmacokinetics of MID was also measured
in a subgroup of 13 subjects following the administra-
tion of an oral dose of 7.5 mg. For the latter subjects,
the two sessions, i.e. the session with the 75-lg dose and
the session with the 7.5-mg dose, were separated by an
interval of at least 1 week and at the most 3 weeks.
Blood sampling
During each session, at approximately 0800 hours,
after an overnight fast, an intravenous catheter was
inserted into a forearm vein, and a blood sample was
taken into a heparinised tube (time 0). The subjects
were asked to drink 100 ml water containing either
0.075 mg or 7.5 mg MID, prepared by diluting 75 ll of
a 1 mg/ml MID solution into 100 ml water or 1.5 ml of
a 5 mg/ml MID solution into 100 ml water, respec-
tively. The subjects then drank an additional 100 ml
water to rinse the glass. After ingestion of 75 lg MID,
blood samples were taken at 0.5, 1, 1.5, 2, 3, 4 and 6 h.
After ingestion of 7.5 mg MID, supplemental blood
samples were taken at 8 h and 24 h (the catheter was
removed after the blood sampling at 8 h, the subjects
returned home but were asked to come back to the
centre for the 24-h blood sample). All blood samplings
were performed with subjects in the supine position.
The subjects were given a breakfast and a meal, if
awake, approximately 1.5 h and 4.5 h, respectively,
after ingestion of the drug. Subjects with the standard
dose of MID were asked to lie on a bed until the
sedative eﬀects of MID became inconsequential. All
subjects were asked to refrain from walking for at least
90 min. After collection, the blood samples were
centrifuged within 1 h, and the plasma samples stored
at )20C until analysis.
Determinations of MID and metabolites
Determination of unconjugated MID, and of total
1OHMID and 4OHMID (unconjugated + conjugated),
was performed using gas chromatography—negative
chemical ionisation mass spectrometry [12]. Total con-
centrations were obtained by enzymatic hydrolysis of the
glucuronic conjugates. The limits of quantiﬁcation, as
deﬁned by the concentration for which the mean value
of replicate determination (n=8) was within 20% of the
actual value, the coeﬃcient of variation less than 20%,
and which gave a signal-to-noise ratio of at least 10,
were found to be 10 pg/ml for the three substances.
Intra- and inter-day coeﬃcients of variation determined
at three concentrations (100 pg/ml, 500 pg/ml, 2 ng/ml)
ranged from 1% to 8% for MID, from 2% to 13% for
1OHMID, and from 1% to 14% for 4OHMID [12] The
percentage theoretical concentrations, which represent
the accuracy of the method, were within ±8% for MID
and 1OHMID, within ±9% for 4OHMID at 500 pg/ml
and 2 ng/ml, and within ±28% for 4OHMID at 100
pg/ml [12]. 1OHMID to MID ratios were calculated
with total concentrations of 1OHMID. These ratios
were then multiplied by 325.8 and divided by 341.8
(the former and the latter values being the molecular
weights of MID and OHMID, respectively).
Genotyping analyses
DNA was isolated using standard methods from blood
drawn into tubes containing 9 ml potassium–ethylene
diamine tetraacetic acid (K-EDTA) and stored at )20C
until use. The CYP3A5*3 allele was determined by real-
time polymerase chain reaction (PCR) with TaqMan
(Applied Biosystems, Rotkreuz, Switzerland) according
to the manufacturer’s instructions. Brieﬂy, the 25-ll
PCR mixture contained 12.5 ll TaqMan Universal PCR
master mix (2· solution containing AmpliTaq Gold
DNA polymerase, AmpErase UNG, dNTPs, and opti-
mised buﬀer), 700 nM forward primer, 800 nM reverse
primer, 2 lM each probe and 100 ng DNA. After an
activation step of AmpErase (50C, 2 min) and
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AmpliTaq Gold enzyme activation (95C, 10 min), 35
PCR cycles were performed with 15 s at 92C and 1 min
at 61C. The primers were 5¢-CCACCCAGCTTAAC-
GAATGC-3¢ (forward) and 5¢-GAAGGGTAATG-
TGGTCCAAACAG-3¢ (reverse), and the probes
were 5¢-TGTCTTTCAaTATCTCT-3¢ (FAM) and
5¢-TGTCTTTCAgTATCTCT-3¢ (VIC).
CYP3A5*6 and 7 alleles were analysed by TaqMan
allelic discrimination assays (Applied Biosystems, Ger-
many). PCR was carried out with 50–60 ng DNA,
900 nM each primer, 200 nM each probe, in a total
25-ll volume of 1· TaqMan Universal PCR Master
Mix. Cycling conditions were 40 cycles of 15 s at 92C
and 60 s at 62C after a 10-min activation step at 95C.
Ampliﬁcation was achieved on a GeneAmp PCR System
9700 employing the 9600 emulation modus, and allele-
speciﬁc detection of the amplicons was performed using
the plate reading function of an ABI PRISM 7700.
Primer and probe combinations for the speciﬁc detection
of CYP3A5*6 and CYP3A5*7 were 5¢-GGC CTA CAG
CAT GGA TGT GAT T-3¢ (forward), 5¢-AAA TAA
TAG CCC ACA TAC TTA TTG AGA GAA AT-3¢
(reverse), 5¢-VIC-AGC ACT AAg AAG TTC CTA AA-
3¢ and 5¢-FAM-AGA GCA CTA AaA AGT TCC TAA-
3¢; and 5¢- CTC AGA TTA TCC AAT TCT GTT TCT
TTC C )3¢ (forward), 5¢-ATT GAT TTC AAC ATC
TTT CTT GCA AGT-3¢ (reverse), 5¢-VIC–CAC CAC
CTa CCT ATG AT-3¢ and 5¢-FAM–CAC CAC CTt
ACC TAT GAT-3¢, respectively.
CYP3A4*1B, *1E, *1F, *2, *4, *5, *6, *8, *11, *12,
*13, *17 and *18 alleles were detected by Dye Termi-
nator sequencing of gene-speciﬁc PCR fragments. PCRs
were carried out in 50-ll reaction volumes employing
20–40 ng DNA template, 1 U Taq polymerase (Qiagen,
Germany), 200 lM dNTP mix (Roth, Karlsruhe, Ger-
many), 1· Taq buﬀer (Qiagen, Hilden, Germany) and
250 nM of primers 5¢-AGA GCC ATG ACA GGG
AAT AAG ACT AGA-3¢ (forward) and 5¢-TGG GCT
ATG TGC ATG GAG CTT-3¢ (reverse) for CY-
P3A4*1B and *1E, 5¢-CCA CTC TTT GGC AAA GAA
CCT GTC T-3¢ (forward) and 5¢-CCC TTC ATG CAA
TCC TAT TGT CCT-3¢ (reverse) for CYP3A4*1F,
5¢-CTA CAA CCA TGG AGA CCT CC-3¢ (forward)
and 5¢-TAC CTG TCC CCA CCA GAT TC-3¢ (reverse)
for CYP3A4*4 and *8, 5¢-TGA CTG GAC ATG TGG
GTT TCC TGT-3¢ (forward) and 5¢-GCT GAT AGC
TAA AAA TGT ATG AGG TCT C-3¢ (reverse) for
CYP3A4*2, *5, *16, *17, 5¢-GAG CCT TCC CGA
ATG CTT CCC A-3¢ (forward) and 5¢-GGA CAT AAC
TGA TGA CCT TCA TCG-3¢ (reverse) for
CYP3A4*11, -*12, and -*13, 5¢-GGA GAT CAA GGA
CCA CGC TTG TG-3¢ (forward) and 5¢-CTC ATC
ATC CTG GAA TAC TTC CTG C-3¢ (reverse) for
CYP3A4*6, and 5¢-CCC AGT GTA CCT CTG AAT
TGC-3¢ (forward) and 5¢-CAG AGC CTT CCT ACA
TAG-3¢ (reverse) for CYP3A4*18. A GeneAmp PCR
System 9700 (Applied Biosystems, Germany) was used
for 34 cycles of 94C (45 s), 62C (45 s) and 72C (60 s)
after an initial denaturation step of 120 s at 94C.
PCR products were cleaned using the QIAquick
puriﬁcation system on a Qiagen BioRobot 9600 (Qiagen,
Hilden, Germany) and 30–80 ng were sequenced in the
forward direction using 5 pmol of the respective PCR
primers and the Big Dye Terminator cycle sequencing
kit (Applied Biosystems, Weiterstadt, Germany) in
10- to 20-ll volumes supplemented by 5% DMSO (v/v).
Cycling conditions were as follows: initial denaturation
at 96C for 10 s, followed by 25 cycles of 96C for 10 s
and 60C for 4 min on a GeneAmp PCR System 9700
(Applied Biosystems, Weiterstadt, Germany). The DNA
sequences of the standard isopropanol-precipitated PCR
fragments were obtained on an automated ABI3700
capillary sequencer (Applied Biosystems, Weiterstadt,
Germany), assembled and SNPs identiﬁed using the
phredPhrap, Consed, and PolyPhred software package
(University of Washington, Seattle, USA).
Data analysis
The concentrations of MID, and of total 1OHMID and
4OHMID determined after each administration were
plotted against time according to the dosage level. The
individual curves were then characterised by their area
under the curve calculated by log-trapezoidal rule with
extrapolation to inﬁnity (AUCinf). All calculations were
performed using the non-compartmental method
implemented in the program Kinetica (version 4.0,
Innaphase, Buckinghamshire, UK). Comparisons
between diﬀerent groups of subjects were performed
using Kruskall-Wallis test (Statistix version 7; Analytical
Software, Tallahassee, FL). Power analysis was
performed using the two-sample t-test power analysis
(NCSS Trial and PASS 2000, NCSS, Kaysville, Utah,
USA). The diﬀerences were appreciated considering a
signiﬁcance level of P<0.05.
Results
Genotype analyses identiﬁed 20 carriers of the
CYP3A5*3 allele among the 21 study subjects (one
homozygous wild-type CYP3A5*1/*1, three heterozy-
gous CYP3A5*1/*3, 17 homozygous CYP3A5*3/*3).
CYP3A5*7 was not detected while CYP3A5*6 was
detected in only one subject of Black-African origin,
who was shown to be heterozygous CYPA5*1/*6. As the
CYP3A5*6 allele generates an mRNA lacking exon 7 [4],
17 subjects could be classiﬁed as CYP3A5 poor
metabolisers (CYP3A5*3/*3) and 4 subjects as hetero-
zygous extensive metabolisers (one CYP3A5*1/*6 and
three CYP3A5*1/*3). CYP3A4*1E, CYP3A4*2, CYP3
A4*4, CYP3A4*5, CYP3A4*6, CYP3A4*8, CYP3
A4*11, CYP3A4*12, CYP3A4*13, CYP3A4*17 and
CYP3A4*18 were not identiﬁed. Among the 21 subjects,
genotype analyses identiﬁed 4 carriers of the
CYP3A4*1B allele (one homozygous CYP3A4*1B/*1B
who was the subject of Black-African origin, three
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heterozygous CYP3A4*1/*1B), and 2 carriers of the
CYP3A4*1F (2 heterozygous CYP3A4*1/*1F).
AUCinf values of MID measured after the 7.5-mg
dose in 13 subjects were (mean±SD, median, range):
67±30 h ng/ml, 61 h ng/ml, 35–135 h ng/ml. After the
75-lg dose in 21 subjects they were: 0.68±0.25 h ng/ml,
0.71 h ng/ml, 0.23–1.17 h ng/ml [11]. When comparing
the group of nine CYP3A5 poor metabolisers with the
four extensive metabolisers who received the 7.5-mg
dose of MID, the mean AUCinf value of MID was lower
in the CYP3A5 extensive (mean±SD, median, range:
55±10 h ng/ml, 58 h ng/ml, 40–63 h ng/ml) than in the
poor (72±34 h ng/ml, 61 h ng/ml, 35–135 h ng/ml)
metabolisers, although this diﬀerence was not statisti-
cally signiﬁcant (P=0.34; Fig. 1). However, the total
1OHMID AUCinf/total 4OHMID AUCinf ratio was
signiﬁcantly higher in the CYP3A5 extensive than in the
poor metaboliser group (19±5, 19, 13–26 versus 12±3,
11, 7–18; P<0.02; Fig. 1). Neither the subject of North
African origin (CYP3A5*3/*3; data not shown) nor the
subject of Black-African origin (CYP3A5*1/*6; Fig. 1)
were outliers when considering their AUCinf value or
their total 1OHMID AUCinf/total 4OHMID AUCinf
ratio. Mean AUCinf values were not signiﬁcantly
diﬀerent between subjects without (73±34 h ng/ml, 61 h
ng/ml, 40–135 h ng/ml) or with the CYP3A4*1B allele
(53±13 h ng/ml, 58 h ng/ml, 35–63 h ng/ml). The two
carriers of the CYP3A4*1F allele did not appear to be
outliers with regard to their AUCinf values when com-
pared with non-carriers of this allele (data not shown).
Finally, a comparison of the AUCinf values or the
30-min MID with total 1OHMID ratio, determined
after the administration of the 75-lg MID dose in the
21 subjects did not show any statistically signiﬁcant
diﬀerences between the diﬀerent CYP3A4 and CYP3A5
genotypes (data not shown).
Discussion
In a previous study, the pharmacokinetics of an oral
dose of 75 lg and 7.5 mg MID was measured in a group
of 21, and in a subgroup of 13 healthy subjects,
respectively [11]. During that study, we validated the use
of the 75-lg oral dose of MID as a phenotyping probe
for CYP3A and showed that the 30-min total 1OHMID
to MID ratio can be reliably used as an indicator of
MID clearance [11]. The aim of the present study was to
genotype the 21 subjects for diﬀerent CYP3A4 and
CYP3A5 alleles, and to determine whether diﬀerences in
MID pharmacokinetics could be demonstrated between
genotypes. With regard to CYP3A4, the absence of
CYP3A4*1E, CYP3A4*2, CYP3A4*4, CYP3A4*5,
CYP3A4*6, CYP3A4*8, CYP3A4*11, CYP3A4*12,
CYP3A4*13, CYP3A4*17 and CYP3A4*18 alleles in
this group of 21 subjects is expected as these SNPs have
been detected at low frequencies in Caucasian and/or
other populations [2, 3, 13, 14, 15]. No change in MID
AUCinf was observed for the four carriers of the
CYP3A4*1B allele which corresponds to a polymor-
phism in the 5¢-promoter (nifedipine-speciﬁc element)
region [16, 17, 18]. The frequency of this allele was
found to be 4% and 67% in Caucasians and black
subjects, respectively [2]. A small diﬀerence (19% de-
crease) of systemic clearance of MID was observed in 10
African-American G/G homozygotes when compared
with 15 European-American A/A homozygotes
(252±53 versus 310±54 ml/min, P=0.02) [18]. The
inclusion of only one homozygous and three heterozy-
gous in the present study is therefore too low to detect
such a small diﬀerence in MID kinetics. With regard to
CYP3A4*1F, the inclusion of only two heterozygous
carriers does not allow to draw a conclusion on the
Fig. 1 Midazolam AUCinf
values (ﬁlled triangle) and total
1-OH-midazolam AUCinf/
4-OH-midazolam AUCinf ratios
(ﬁlled square) measured in four
CYP3A5 extensive metabolisers
(CYP3A5*1/*6 and
CYP3A5*1/*3) and nine
CYP3A5 poor metabolisers
(CYP3A5*3/*3) after the oral
administration of 7.5 mg
midazolam. The mean value is
indicated in each group by a
bar. The subject of Black-
African origin (CYP3A5*1/*6
and CYP3A4*1B/*1B) is
indicated by empty ﬁgures
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absence of inﬂuence of this allele on MID AUCinf, as
noted in the present study, but no particular phenotype
has previously been associated with this allele [15].
With regard to CYP3A5, the presence of the
CYP3A5*6 allele in the lone subject of Black-African
origin is in accordance with the predominance of this
SNP in this ethnic group compared with Caucasians [4,
5]. Although a lower mean AUCinf value was measured
in the CYP3A5 extensive metabolisers relative to the
poor metabolisers after the 7.5-mg dose, this diﬀerence
was not statistically signiﬁcant. This lack of inﬂuence of
the CYP3A5 genotype on MID pharmacokinetics could
ﬁrst be due to the absence of homozygous extensive
metabolisers (CYP3A5*1/*1). It must be mentioned that
this low frequency of homozygous extensive metabolis-
ers is in agreement with other studies in Caucasians [4,
5]. Second, the number of subjects included in the
present study could be too low and lack the statistical
power to detect a signiﬁcant diﬀerence. Thus, a power
analysis indicated that with a mean±SD value of
72±34 h ng/ml for the AUCinf in the extensive
metaboliser after the 7.5-mg dose (see Results), the
inclusion of four extensive and nine poor metabolisers
allows the achievement of an 80% power to detect a
twofold diﬀerence in the mean AUCinf between the two
groups with a signiﬁcance level (alpha) of 0.05 (one-
sided t-test). As a less than twofold diﬀerence was
measured between the two groups in the present study,
the inclusion of a higher number of subjects (i.e. for
example 27 in each group) would have been necessary.
However, the results of the present study are in agree-
ment with those of a recent study in Chinese, which
found no signiﬁcant diﬀerences in the pharmacokinetics
of MID, and 1OHMID between CYP3A5 poor
metabolisers (CYP3A5*3/*3, n=14) and heterozygous
extensive metabolisers (CYP3A5*1/*3, n=12) [7]. In
another recent study with 57 healthy men and women of
either European-American or African-American ances-
try genotyped for CYP3A4*1B, CYP3A5*3, CYP3A5*6
and CYP3A5*7, no association was noted between any
genotypes and MID or erythromycin metabolic elimi-
nation [8]. However, it has been suggested that the
presence of theCYP3A4*1B allele and the inversely linked
CYP3A5*3 polymorphism might inﬂuence the induction
of oral clearance of MID by rifampicin [8]. In the present
study, four subjects were also treated with rifampicin
during a separate session [11]. However, as all four sub-
jects were CYP3A5 poor metabolisers (CYP3A5*3/*3),
no data supporting a genetic inﬂuence on the induction
of CYP3A activity could be demonstrated.
Finally, and interestingly, the signiﬁcantly higher to-
tal 1OHMID AUCinf/total 4OHMID AUCinf ratios
measured in the present study in the extensive relative to
the poor metabolisers are in agreement with in vitro data
showing that microsomal samples containing CYP3A5
and CYP3A4 exhibited a greater ratio of 1OHMID to
4OHMID compared with samples containing CYP3A4
alone [4, 19]. This result is explained by the regioselec-
tivity of CYP3A5 in favour of 1OHMID relative to
4OHMID, a selectivity that depends on MID concen-
tration [19, 20]. In the present study, with the 7.5-mg
dose (pharmacokinetic parameters of 4OHMID were
not assessable with the 75-lg dose; [11]), although the
mean total 1OHMID/total 4OHMID AUCinf ratios
were signiﬁcantly diﬀerent between both groups, the
largely overlapping ranges prevented the use of this ratio
as a discriminating factor between subjects without and
with CYP3A5 activity.
In summary, in this group of 21 healthy subjects, the
presently known CYP3A4 and CYP3A5 genotypes do
not suﬃciently reﬂect the inter-individual variability in
the activity of these two isozymes.
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